OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 15.39 |
| Open | 15.38 |
| Bid | 2.00 x 900 |
| Ask | 17.00 x 1000 |
| Day's Range | 15.10 - 15.59 |
| 52 Week Range | 12.75 - 32.28 |
| Volume | 9,463 |
| Avg. Volume | 38,690 |
| Market Cap | 58.477M |
| Beta (3Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.00 |
- Simply Wall St.•26 days ago
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
Roger Crystal has been the CEO of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
- GlobeNewswire•27 days ago
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Insider Monkey•last month
Granite Point Capital’s Returns, AUM, and Holdings
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
- Zacks Small Cap Research•last month
OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…
On November 5, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced that the last patient has completed their last visit in the Phase 2 trial of OPNT001, a naloxone nasal spray, in bulimia nervosa (BN). BN is a serious and potentially life-threatening eating disorder characterized by a cycle of binge eating and purging. BN affects approximately 1-2% of the adult population with 80% of those affected being female.
- GlobeNewswire•last month
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Nov. 07, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
- GlobeNewswire•last month
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that the Last Patient, Last Visit (LPLV) occurred on November 2, 2018, in its Phase 2 clinical trial of OPNT001, a naloxone nasal spray, for the treatment of Bulimia Nervosa. Opiant expects to report top-line data from this trial in the first quarter of 2019.
- GlobeNewswire•last month
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
SANTA MONICA, Calif., Nov. 01, 2018 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that Opiant’s Chief Scientific Officer, Phil Skolnick, Ph.D., D.Sc. The panel will take place on Monday, October 29, 2018, at 3:30 PM ET. The BARDA Chemical Threats program has made an amendment to the BARDA Broad Agency Announcement to seek opioid countermeasures with new mechanisms of action. In this session, BARDA team members will bring together drug developers and stakeholders for an open discussion on critical factors and enablers.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that researchers at the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) and SUNY Upstate Medical University in Syracuse, NY, have been awarded a grant by the National Institutes of Health (NIH) to advance OPNT005, a heroin vaccine candidate, through Phase 1/2a clinical trials to assess its safety and efficacy. OPNT005 was co-developed by researchers at MHRP and the National Institute on Drug Abuse (NIDA), part of the NIH. Opiant acquired exclusive development and commercialization rights to this heroin vaccine candidate in 2016. By binding heroin in the blood and thus reducing its passage into the brain, antibodies produced in response to the vaccine can block the euphoria and addictive effects of heroin and other commonly misused opioids. In preclinical studies, the vaccine attenuated the effects of heroin in mice and rats for periods of up to three months.
- Zacks Small Cap Research•2 months ago
OPNT: Contract with BARDA to Support Develop of OPNT003…
On September 20, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced it has entered into a $4.6 million contract with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response. OPNT003 is a nasally administered formulation of nalmefene, a potent and long-acting opioid antagonist that is currently being developed as a treatment for opioid overdose. The BARDA contract is designed to cover those expenses that are not covered by the previously announced $7.4 million grant from the National Institute on Drug Abuse (NIDA).
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, today announced the closing of its previously announced underwritten public offering of 811,764 shares of its common stock, including 105,882 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $17.00 per share. The public offering was made pursuant to a shelf registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission. This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com.
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
SANTA MONICA, Calif., Sept. 26, 2018 -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and.
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, today announced the pricing of an underwritten public offering of 705,882 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Opiant, are expected to be approximately $12 million. In addition, Opiant granted the underwriter a 30-day option to purchase up to 105,882 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
- Benzinga•3 months ago
The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Opiant also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering, at the public offering price, less the underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
- Benzinga•3 months ago
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6 million, with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate Opiant’s development of OPTN003, its lead product candidate. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. In the early 2000s, fentanyl vapor was used by Russian forces to end a hostage standoff with Chechen rebels, resulting in 117 deaths and hundreds more hospitalized, illustrating the potential for weaponizing synthetic opioids. The contract with BARDA will allow for accelerated development of OPNT003 as a medical countermeasure in the event of a fentanyl chemical attack.
- Simply Wall St.•3 months ago
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
If you own shares in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. receives tiered royalties. Shares of Sophiris Bio also saw big gains after announcing updates on a phase 2b Localized Prostate Cancer Trial.
- Zacks Small Cap Research•4 months ago
OPNT: Adapt Pharma® Acquired for $650 Million…
On August 28, 2018, Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million with the potential for another $100 million in sales-based milestones through 2022. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. (OPNT) receives tiered royalties. Emergent also announced that projected 2019 revenues for NARCAN® Nasal Spray will be $200-$220 million, net of royalty payments to Opiant.
- Zacks Small Cap Research•4 months ago
OPNT: Increasing Royalties from NARCAN® Nasal Spray…
Earlier in 2018, Opiant (OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development of OPNT003, a long-lasting opioid antagonist for the treatment of opioid overdose. Based on its favorable pharmacokinetic profile, we believe OPNT003 could become a novel opioid overdose treatment, particularly for overdoses caused by synthetic opioids such as fentanyl and its derivatives. The following chart shows the number of overdose deaths in the U.S. from certain drugs, with the rapid rise in deaths from synthetic opioids just since 2013 particularly striking.
